Vaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant acinetobacter baumannii

Infection and Immunity

Volumn 79, Issue 1, 2011, Pages 518-526

  McConnell, Michael J ^a   Domínguez Herrera, Juan ^a   Smani, Younes ^a   López Rojas, Rafael ^a   Docobo Pérez, Fernando ^a   Pachón, Jerónimo ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; OUTER MEMBRANE COMPLEX VACCINE; OUTER MEMBRANE PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BACTERIAL LOAD; BACTERIAL MEMBRANE; BACTERIUM ISOLATE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PROTECTION; CYTOKINE RELEASE; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPSIS; VACCINATION;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; MICE; MICE, INBRED C57BL; TIME FACTORS;

EID: 78650867908     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00741-10     Document Type: Article

References (40)

1. Adams, M. D., G. C. Nickel, S. Bajaksouzian, H. Lavender, A. R. Murthy, M. R. Jacobs, and R. A. Bonomo. 2009. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob. Agents Chemother. 53:3628-3634.
2. Batson, H. C., M. Landy, and M. Brown. 1950. Determination of differences in virulence of strains of Salmonella typhosa; a comparison of methods. J. Exp. Med. 91:219-229.
3. Bebbington, C., and G. Yarranton. 2008. Antibodies for the treatment of bacterial infections: current experience and future prospects. Curr. Opin. Biotechnol. 19:613-619.
4. Bertot, G. M., M. A. Restelli, L. Galanternik, R. C. Aranibar Urey, M. A. Valvano, and S. Grinstein. 2007. Nasal immunization with Burkholderia multivorans outer membrane proteins and the mucosal adjuvant adamantyl-amide dipeptide confers efficient protection against experimental lung infections with B. multivorans and B. cenocepacia. Infect. Immun. 75:2740-2752.
5. Castanheira, M., H. S. Sader, L. M. Deshpande, T. R. Fritsche, and R. N. Jones. 2008. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase-and metallo-beta-lacta-mase- producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother. 52:570-573.
6. Choi, C. H., J. S. Lee, Y. C. Lee, T. I. Park, and J. C. Lee. 2008. Acinetobacter baumannii invades epithelial cells and outer membrane protein A mediates interactions with epithelial cells. BMC Microbiol. 8:216.
7. Cornfield, J. 1950. The Probit method. Science 111:42-43.
8. Doring, G., and G. B. Pier. 2008. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine 26:1011-1024.
9. Fernandez-Cuenca, F., A. Pascual, A. Ribera, J. Vila, G. Bou, J. M. Cisneros, J. Rodriguez-Bano, J. Pachon, and L. Martinez-Martinez. 2004. Clonal diversity and antimicrobial susceptibility of Acinetobacter baumannii isolated in Spain. A nationwide multicenter study: GEIH-Ab project (2000). Enferm. Infecc. Microbiol. Clin. 22:267-271.
10. Fransen, F., C. J. Boog, J. P. van Putten, and P. van der Ley. 2007. Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B. Infect. Immun. 75:5939-5946.
11. Garcia-Garmendia, J. L., C. Ortiz-Leyba, J. Garnacho-Montero, F. J. Jimenez-Jimenez, J. Monterrubio-Villar, and M. Gili-Miner. 1999. Mortality and the increase in length of stay attributable to the acquisition of Acinetobacter in critically ill patients. Crit. Care Med. 27:1794-1799.
12. Gardy, J. L., M. R. Laird, F. Chen, S. Rey, C. J. Walsh, M. Ester, and F. S. Brinkman. 2005. PSORTb v. 2.0: expanded prediction of bacterial protein subcellular localization and insights gained from comparative proteome analysis. Bioinformatics 21:617-623.
13. Gautom, R. K. 1997. Rapid pulsed-field gel electrophoresis protocol for typing of Escherichia coli O157:H7 and other gram-negative organisms in 1 day. J. Clin. Microbiol. 35:2977-2980.
14. Gaynes, R., and J. R. Edwards. 2005. Overview of nosocomial infections caused by gram-negative bacilli. Clin. Infect. Dis. 41:848-854.
15. Go, E. S., C. Urban, J. Burns, B. Kreiswirth, W. Eisner, N. Mariano, K. Mosinka-Snipas, and J. J. Rahal. 1994. Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 344:1329-1332.
16. Ho, P. L., V. C. Cheng, and C. M. Chu. 2009. Antibiotic resistance in community-acquired pneumonia caused by Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus, and Acinetobacter baumannii. Chest 136:1119-1127.
17. Huntley, J. F., P. G. Conley, D. A. Rasko, K. E. Hagman, M. A. Apicella, and M. V. Norgard. 2008. Native outer membrane proteins protect mice against pulmonary challenge with virulent type A Francisella tularensis. Infect. Im-mun. 76:3664-3671.
18. Jang, I. J., I. S. Kim, W. J. Park, K. S. Yoo, D. S. Yim, H. K. Kim, S. G. Shin, W. H. Chang, N. G. Lee, S. B. Jung, D. H. Ahn, Y. J. Cho, B. Y. Ahn, Y. Lee, Y. G. Kim, S. W. Nam, and H. S. Kim. 1999. Human immune response to a Pseudomonas aeruginosa outer membrane protein vaccine. Vaccine 17:158-168.
19. Kim, D. K., J. J. Kim, J. H. Kim, Y. M. Woo, S. Kim, D. W. Yoon, C. S. Choi, I. Kim, W. J. Park, N. Lee, S. B. Jung, B. Y. Ahn, S. W. Nam, S. M. Yoon, and W. J. Choi. 2000. Comparison of two immunization schedules for a Pseudo-monas aeruginosa outer membrane proteins vaccine in burn patients. Vaccine 19:1274-1283.
20. Marti, S., J. Sanchez-Cespedes, E. Oliveira, D. Bellido, E. Giralt, and J. Vila. 2006. Proteomic analysis of a fraction enriched in cell envelope proteins of Acinetobacter baumannii. Proteomics 6(Suppl. 1):S82-S87.
21. Martin, R. M., J. L. Brady, and A. M. Lew. 1998. The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice. J. Immunol. Methods 212:187-192.
22. McConnell, M. J., X. Danthinne, and M. J. Imperiale. 2006. Characterization of a permissive epitope insertion site in adenovirus hexon. J. Virol. 80:5361-5370.
23. McConnell, M. J., P. C. Hanna, and M. J. Imperiale. 2006. Cytokine response and survival of mice immunized with an adenovirus expressing Bacillus anthracis protective antigen domain 4. Infect. Immun. 74:1009-1015.
24. Munoz-Price, L. S., and R. A. Weinstein. 2008. Acinetobacter infection. N. Engl. J. Med. 358:1271-1281.
25. Ong, C. W., D. C. Lye, K. L. Khoo, G. S. Chua, S. F. Yeoh, Y. S. Leo, P. A. Tambyah, and A. C. Chua. 2009. Severe community-acquired Acinetobacter baumannii pneumonia: an emerging highly lethal infectious disease in the Asia-Pacific. Respirology 14:1200-1205.
26. Pantophlet, R., L. Brade, L. Dijkshoorn, and H. Brade. 1998. Specificity of rabbit antisera against lipopolysaccharide of Acinetobacter. J. Clin. Micro-biol. 36:1245-1250.
27. Pier, G. B. 1985. Pseudomonas aeruginosa surface polysaccharide vaccines. New therapeutic approaches from basic research. Antibiot. Chemother. 36: 157-167.
28. Rodriguez-Hernandez, M. J., J. Pachon, C. Pichardo, L. Cuberos, J. Ibanez-Martinez, A. Garcia-Curiel, F. J. Caballero, I. Moreno, and M. E. Jimenez-Mejias. 2000. Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. J. Anti-microb. Chemother. 45:493-501.
29. Rodriguez-Ortega, M. J., N. Norais, G. Bensi, S. Liberatori, S. Capo, M. Mora, M. Scarselli, F. Doro, G. Ferrari, I. Garaguso, T. Maggi, A. Neumann, A. Covre, J. L. Telford, and G. Grandi. 2006. Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat. Biotechnol. 24:191-197.
30. Schaffer, A. C., and J. C. Lee. 2008. Vaccination and passive immunisation against Staphylococcus aureus. Int. J. Antimicrob. Agents 32(Suppl. 1):S71-S78.
31. Schaub, I. G., and F. D. Hauber. 1948. A biochemical and serological study of a group of identical unidentifiable gram-negative bacilli from human sources. J. Bacteriol. 56:379-385.
32. Stranger-Jones, Y. K., T. Bae, and O. Schneewind. 2006. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc. Natl. Acad. Sci. U.S.A. 103:16942-16947.
33. Taccone, F. S., H. Rodriguez-Villalobos, D. De Backer, V. De Moor, J. Deviere, J. L. Vincent, and F. Jacobs. 2006. Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur. J. Clin. Microbiol. Infect. Dis. 25:257-260.
34. Valencia, R., L. A. Arroyo, M. Conde, J. M. Aldana, M. J. Torres, F. Fer-nandez-Cuenca, J. Garnacho-Montero, J. M. Cisneros, C. Ortiz, J. Pachon, and J. Aznar. 2009. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect. Control Hosp. Epidemiol. 30:257-263.
35. Vaneechoutte, M., L. Dijkshoorn, I. Tjernberg, A. Elaichouni, P. de Vos, G. Claeys, and G. Verschraegen. 1995. Identification of Acinetobacter genomic species by amplified ribosomal DNA restriction analysis. J. Clin. Microbiol. 33:11-15.
36. Vila, J., S. Marti, and J. Sanchez-Cespedes. 2007. Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii. J. Antimicrob. Chemother. 59:1210-1215.
37. Vila, J., and J. Pachon. 2008. Therapeutic options for Acinetobacter bauman-nii infections. Expert Opin. Pharmacother. 9:587-599.
38. Wessel, D., and U. I. Flugge. 1984. A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal. Biochem. 138:141-143.
39. Wisplinghoff, H., M. B. Edmond, M. A. Pfaller, R. N. Jones, R. P. Wenzel, and H. Seifert. 2000. Nosocomial bloodstream infections caused by Acineto-bacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin. Infect. Dis. 31:690-697.
40. Zavascki, A. P., C. G. Carvalhaes, R. C. Picao, and A. C. Gales. 2010. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev. Anti Infect. Ther. 8:71-93.